The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease

NCT01268241 · clinicaltrials.gov ↗
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

CENTOGENE GmbH Rostock